scholarly journals Improving Cognition via Exercise (ICE): Study Protocol for a Multi-Site, Parallel-Group, Single-Blind, Randomized Clinical Trial Examining the Efficacy of Aerobic Exercise to Improve Neurocognition, Daily Functioning, and Biomarkers of Cognitive Change in Individuals with Schizophrenia

2019 ◽  
Keyword(s):  
Clinical Trial ◽  
Aerobic Exercise ◽  
Randomized Clinical Trial ◽  
Study Protocol ◽  
Cognitive Change ◽  
Daily Functioning ◽  
Parallel Group ◽  
Single Blind

scholarly journals Correction to: Effect of aerobic exercise prior to modified constraint-induced movement therapy outcomes in individuals with chronic hemiparesis: a study protocol for a randomized clinical trial

BMC Neurology ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Erika Shirley Moreira da Silva ◽  
Gabriela Lopes Santos ◽  
Aparecida Maria Catai ◽  
Alexandra Borstad ◽  
Natália Pereira Duarte Furtado ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Aerobic Exercise ◽  
Randomized Clinical Trial ◽  
Study Protocol ◽  
Movement Therapy ◽  
Therapy Outcomes ◽  
Constraint Induced Movement Therapy

Following publication of the original article [1], the authors reported an error in Table 2 wherein the item numbering in the first column is wrong.

scholarly journals Effect of aerobic exercise prior to modified constraint-induced movement therapy outcomes in individuals with chronic hemiparesis: a study protocol for a randomized clinical trial

BMC Neurology ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Erika Shirley Moreira da Silva ◽  
Gabriela Lopes Santos ◽  
Aparecida Maria Catai ◽  
Alexandra Borstad ◽  
Natália Pereira Duarte Furtado ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Aerobic Exercise ◽  
Randomized Clinical Trial ◽  
Study Protocol ◽  
Movement Therapy ◽  
Therapy Outcomes ◽  
Constraint Induced Movement Therapy

scholarly journals Suicide Reduction in Schizophrenia via Exercise (SUnRISE): Study Protocol for A Multi-Site, Single-Blind, Randomized Clinical Trial of Aerobic Exercise for Suicide Risk Reduction in Individuals With Schizophrenia

2020 ◽  
Author(s):  
Katie Beck-Felts ◽  
Marianne Goodman ◽  
Luz Ospina ◽  
Melanie Wall ◽  
Joseph Mc Evoy ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Aerobic Exercise ◽  
Risk Reduction ◽  
Randomized Clinical Trial ◽  
Suicide Risk ◽  
Rating Scale ◽  
Psychotherapeutic Treatment ◽  
Exercise Interventions ◽  
The Impact ◽  
Single Blind

Abstract Background: Suicide risk among individuals with schizophrenia (SZ) is intractably high, with over 40% of individuals attempting to take their own lives during their lifetime and an estimated 5-10% completing suicide. At present, available pharmacological and psychotherapeutic treatments offer limited risk reduction benefits, thus there remain an urgent need to explore novel interventions that will ameliorate this risk. Aerobic exercise (AE) has been shown to improve a number of predictors of suicide risk (e.g., depressed mood, sleeping difficulties). As individuals with SZ display a highly sedentary lifestyle, AE may reduce suicide risk. Methods: Employing a multi-site, single-blind, randomized clinical trial design, we will examine the impact of AE on risk for suicide and related variables in individuals with SZ. Participants will be randomized to one of two 12-week exercise interventions: AE or a stretching and toning (ST) control intervention. Primary outcome measures will include suicide risk (Columbia Suicide Severity Rating Scale, C-SSRS) and aerobic fitness (VO2max), along with additional measures of suicide risk, mood, emotion regulation, sleep, cognition, and physical activity, with assessments completed at baseline and after 6- and 12-weeks of interventions.Discussion: It is hypothesized that AE will reduce suicide risk among individuals with SZ. This study may offer support for a more efficacious treatment method for this population in addition to the pre-existing pharmacological and psychotherapeutic treatment regimens. Trial Registration: Clinicaltrials.gov, NCT03270098. Registered September 1, 2017.

scholarly journals Suicide Reduction in Schizophrenia via Exercise (SUnRISE): study protocol for a multi-site, single-blind, randomized clinical trial of aerobic exercise for suicide risk reduction in individuals with schizophrenia

Trials ◽  
2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Katie Beck-Felts ◽  
Marianne Goodman ◽  
Luz H. Ospina ◽  
Melanie Wall ◽  
Joseph McEvoy ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Aerobic Exercise ◽  
Risk Reduction ◽  
Randomized Clinical Trial ◽  
Suicide Risk ◽  
Rating Scale ◽  
Psychotherapeutic Treatment ◽  
Exercise Interventions ◽  
The Impact ◽  
Single Blind

Abstract Background Suicide risk among individuals with schizophrenia (SZ) is intractably high, with over 40% of individuals attempting to take their own lives during their lifetime and an estimated 5–10% completing suicide. At present, available pharmacological and psychotherapeutic treatments offer limited risk reduction benefits, and thus, there remains an urgent need to explore novel interventions that will ameliorate this risk. Aerobic exercise (AE) has been shown to improve a number of predictors of suicide risk (e.g., depressed mood, sleeping difficulties). As individuals with SZ display a highly sedentary lifestyle, AE may reduce suicide risk. Methods Employing a multi-site, single-blind, randomized clinical trial design, we will examine the impact of AE on risk for suicide and related variables in individuals with SZ. Participants will be randomized to one of two 12-week exercise interventions: AE or a stretching and toning (ST) control intervention. Primary outcome measures will include suicide risk (Columbia Suicide Severity Rating Scale, C-SSRS) and aerobic fitness (VO2max), along with additional measures of suicide risk, mood, emotion regulation, sleep, cognition, and physical activity, with assessments completed at baseline and after 6 and 12 weeks of interventions. Discussion It is hypothesized that AE will reduce suicide risk among individuals with SZ. This study may offer support for a more efficacious treatment method for this population in addition to the pre-existing pharmacological and psychotherapeutic treatment regimens. Trial registration Clinicaltrials.gov, NCT03270098. Registered on September 1, 2017.

Sign in / Sign up

Export Citation Format

Share Document